Clinical Trial Update: Utilization of the Viracor® Assay for Valganciclovir Prophylaxis in CMV High Risk Kidney Transplant Recipients

View source ↗

Summary

This clinical trial update reports the completion of a study evaluating the Viracor CMV assay to guide valganciclovir prophylaxis in high-risk kidney transplant…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection

Drugs mentioned

• Valcyte (valganciclovir)
• Viracor CMV assay

Snippet

Sponsor: Piedmont Healthcare | Conditions: Kidney Transplant; Complications | Status: COMPLETED